

1
2
3
4

TITLE PAGE

- Korean Journal for Food Science of Animal Resources -
Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
Article Title	Bioconversion Products of Whey by Lactic Acid Bacteria Exert Anti-adipogenic Effect
Running Title (within 10 words)	LAB-bioconverted whey exhibits anti-adipogenic effect
Author	Ji Soo Lee [†] , In Kyung Hyun [†] , Ji-Won Yoon, Hye-Jin Seo, Seok-Seong Kang
Affiliation	Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, 10326, Korea
Special remarks – if authors have additional information to inform the editorial office	[†] These authors contributed equally to this work
ORCID (All authors must have ORCID) https://orcid.org	Ji Soo Lee (https://orcid.org/0000-0002-4579-6570) In Kyung Hyun (https://orcid.org/0000-0002-9417-6757) Ji-Won Yoon (http://orcid.org/0000-0002-5554-2259) Hye-Jin Seo (https://orcid.org/0000-0002-0460-6857) Seok-Seong Kang (https://orcid.org/0000-0001-7029-9122)
Conflicts of interest List any present or potential conflict s of interest for all authors. (This field may be published.)	The authors declare no potential conflict of interest.
Acknowledgements State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available. (This field may be published.)	This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-added Food Technology Development Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (318091-03-2-HD050).
Author contributions (This field may be published.)	Conceptualization: Kang SS. Data curation: Lee JS, Hyun IK, Yoon JW, Seo HJ, Kang SS. Formal analysis: Lee JS, Hyun IK, Yoon JW, Seo HJ. Methodology: Yoon JW, Seo HJ, Kang SS. Software: Lee JS, Hyun IK. Validation: Lee JS, Hyun IK, Yoon JW, Seo HJ. Investigation: Lee JS, Hyun IK, Yoon JW, Seo HJ.

	<p>Writing - original draft: Lee JS, Hyun IK.</p> <p>Writing - review & editing: Lee JS, Hyun IK, Yoon JW, Seo HJ, Kang SS.</p>
<p>Ethics approval (IRB/IACUC) (This field may be published.)</p>	<p>This manuscript does not require IRB/IACUC approval because there are no human and animal participants.</p>

5

6 **CORRESPONDING AUTHOR CONTACT INFORMATION**

For the <u>corresponding</u> author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Seok-Seong Kang
Email address – this is where your proofs will be sent	sskang@dongguk.edu
Secondary Email address	Kangelo72@gmail.com
Postal address	Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10326, Korea
Cell phone number	+82-10-3669-6409
Office phone number	+82-31-961-5150
Fax number	+82-31-961-5108

7

8

9 **Abstract**

10 Microbial bioconversion using lactic acid bacteria provides several human health benefits.
11 Although whey and whey-derived bioactive compounds can contribute to an improvement in
12 human health, the potential anti-obesity effect of whey bioconversion by lactic acid bacteria
13 has not been well studied. This study aimed to investigate whether bioconversion of whey by
14 *Pediococcus pentosaceus* KI31 and *Lactobacillus sakei* KI36 (KI31-W and KI36-W,
15 respectively) inhibits 3T3-L1 preadipocyte differentiation. Both KI31-W and KI36-W reduced
16 intracellular lipid accumulation significantly, without decreasing 3T3-L1 preadipocyte
17 proliferation. In addition, obesity-related transcription factor (peroxisome proliferator-activated
18 receptor γ) and genes (adipocyte fatty acid-binding protein and lipoprotein lipase) were down-
19 regulated significantly in 3T3-L1 cells in the presence of KI31-W and KI36-W. Collectively,
20 these results suggest that bioconversion of whey by lactic acid bacteria exhibits anti-adipogenic
21 activity and may be applied as a therapeutic agent for obesity.

22
23 **Keywords:** bioconversion, whey, lactic acid bacteria, obesity, 3T3-L1 preadipocyte
24

25 **Introduction**

26 Whey is the principal by-product of cheese manufacture. The huge quantities of whey
27 produced by the dairy industry during cheese-making are difficult to dispose of, creating a
28 serious environmental issue (Domingues et al., 1999; Marshall, 2004). However, whey contains
29 a rich and heterogeneous mix of proteins, including β -lactoglobulin, α -lactalbumin, bovine
30 serum albumin, glycomacropeptide, immunoglobulins, and lactoferrin (Walzem et al., 2002).
31 Thus, this protein provides antimicrobial activity, immunomodulation, improved muscle
32 strength, and lessens several risk factors for metabolic diseases (Bjornshave and Hermansen,
33 2014; Marshall, 2004).

34 Bioconversion is known as a structural modification of chemical compounds (Asha and
35 Vidyavathi, 2009). The recognition of bioconversion by microbes as an important tool has
36 increased in the chemical, pharmaceutical, cosmetic, and food industries (Hegazy et al., 2015;
37 Smitha et al., 2017). Lactic acid bacteria (LAB) have been traditionally used as the starter
38 culture in fruits, vegetables, and dairy products, as well as probiotics (Sornplang and
39 Piyadeatsoontorn, 2016). In addition, various enzymes, such as β -glucosidase, produced by
40 LAB also utilize nutritional substances, providing benefits to the host (Lin et al., 2002).
41 Furthermore, LAB associated with the bioconversion provide health-promoting attributes
42 (Boguta et al., 2014; Lee and Paik, 2017).

43 Obesity is defined as the excessive accumulation of fat in the adipose tissue as a result of the
44 imbalance between energy intake and expenditure (Spiegelman and Flier, 2001). The surplus
45 energy derived from the metabolism of dietary carbohydrates, fats, and proteins leads to
46 hypertrophic and hyperplastic adipose tissue expansion (Yang et al., 2019). The dramatic
47 increasing incidence of metabolic diseases, including obesity, imposes a growing economic and
48 medical burden on societies. Therefore, the biological components produced during whey

49 bioconversion by LAB might be beneficial for metabolic diseases, such as obesity. In this study,
50 we investigated whether bioconversion of whey using two LAB, *Pediococcus pentosaceus* and
51 *Lactobacillus sakei*, reduces adipogenesis of preadipocytes.

52

53 **Materials and Methods**

54 **Bioconversion of whey by LAB**

55 Two LAB isolated from kimchi (*P. pentosaceus* KI 31 and *L. sakei* KI 36) were kindly
56 provided by Dr. Sang-Dong Lim (Korea Food Research Institute, Wanju, Korea). Both LAB
57 were cultured in de Man–Rogosa–Sharpe (MRS) medium (Neogen, Lansing, MI, USA) at 37°C.
58 Whey bioconversion medium was prepared by adding 10% (w/v) whey powder (Samik Dairy
59 & Food Co., Ltd., Seoul, Korea) to distilled water, followed by pasteurization at 80°C for 1 min.
60 The whey bioconversion medium was inoculated by either *P. pentosaceus* KI 31 or *L. sakei* KI
61 36 (1%) and incubated at 37°C for 24 h. After incubation, cell-free supernatants were collected
62 by centrifugation and adjusted to pH 6.5 with 1N NaOH. The filtrate was obtained by passing
63 the cell-free supernatants through a syringe filter. Protein concentrations of *P. pentosaceus* KI
64 31- and *L. sakei* KI 36-bioconverted whey (KI 31-W and KI 36-W, respectively) were measured
65 using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA).

66

67 **Cell culture and differentiation of preadipocytes**

68 The mouse preadipocyte cell line, 3T3-L1, was purchased from the Korean Cell Line Bank
69 (Seoul, Korea) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented
70 with 10% bovine calf serum (BCS), 100 U/mL penicillin, and 100 µg/mL streptomycin
71 (HyClone, Logan, UT, USA) at 37°C in humidified air containing 5% CO₂. For adipocyte
72 differentiation, 2-day post-confluent 3T3L-1 cells were stimulated with different concentrations

73 of KI 31-W or KI 36-W in DMEM supplemented with 10% BCS, 0.5 mM 3-isobutyl-1-
74 methylxanthine, 1 μ M dexamethasone, and 5 μ g/mL insulin (day 0). The cells were re-
75 stimulated with KI 31-W or KI 36-W on day 3 and re-fed every 3 days with DMEM
76 supplemented with 10% BCS and 5 μ g/mL insulin. After incubation for 6 days, the medium
77 was replaced with DMEM supplemented with 10% fetal bovine serum and antibiotics, and the
78 cells were further incubated for 3 days.

79

80 **Cell viability assay**

81 The 3T3L-1 cells were seeded on a 96-well culture plate and grown for 48 h. After the
82 treatment with the different concentrations of KI 31-W or KI 36-W for 24 h, MTT (3-[4,5-
83 dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) solution (0.5 mg/mL) was added to
84 the medium and incubated at 37°C for 4 h. The resulting formazan dark purple crystal products
85 were dissolved in 100 μ L of dimethyl sulfoxide and the absorbance was measured at 570 nm
86 using a microplate reader (Allsheng, Hangzhou, China).

87

88 **Oil Red O staining**

89 3T3-L1 cells treated with KI 31-W or KI 36-W were washed with phosphate-buffered saline
90 and fixed with 10% formaldehyde for 1 h. After removing the formaldehyde, the cells were
91 washed with 60% isopropanol and stained with Oil Red O solution (Sigma–Aldrich, St. Louis,
92 MO, USA) for 30 min. Quantification of lipid accumulation was measured at 492 nm using a
93 microplate reader (Allsheng). Microscopic images were also captured to visualize red oil
94 droplet staining in differentiated 3T3-L1 cells treated with or without KI 31-W or KI 36-W. In
95 addition, the lipid accumulation of 3T3-L1 cells treated by non-bioconverted whey was also
96 determined by Oil Red O staining described above.

97

98 **SDS-PAGE**

99 Non-bioconverted whey and bioconversion of whey by *P. pentosaceus* KI 31 or *L. sakei* KI
100 36 (15 µL each) were loaded on the gel and separated using 10% SDS-PAGE. The separated
101 proteins were visualized by Coomassie blue staining.

102

103 **Real-time reverse transcription-polymerase chain reaction (RT-PCR)**

104 After the differentiation of 3T3L-1 cells treated with the different concentrations of KI 31-
105 W or KI 36-W, total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
106 Then, complementary DNA was synthesized using total RNA (5 µg), random hexamers, and
107 reverse transcriptase (Promega, Madison, WI, USA). Afterward, real-time PCR was performed
108 with SYBR Green Real-Time PCR Master Mix (Toyobo, Osaka, Japan) using a Bio-Rad CFX
109 thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). The following sequences of
110 specific primers were used in this study. Peroxisome proliferator-activated receptor γ (PPAR γ)
111 (forward: 5'-AAGGGTGCCAGTTTCGATCC-3', reverse: 5'-
112 TCCTTGGCCCTCTGAGATGA-3'), adipocyte fatty acid-binding protein (aP2) (forward: 5'-
113 GCCCAACATGATCATCAGCG-3', reverse: 5'-TGGTCGACTTTCCATCCCAC-3'),
114 lipoprotein lipase (LPL) (forward: 5'-AACATTCCCTTCACCCTGCC-3', reverse: 5'-
115 GTCTCTCCGGCTTTCACCTCG-3'), and β -actin (forward: 5'-
116 TACAGCTTCACCACCACAGC-3', reverse: 5'-GGAAAAGAGCCTCAGGGCAT-3'). After
117 initial heating at 95°C for 10 s, 40 cycles of PCR (95°C for 5 s and 60°C for 31 s) were
118 performed, followed by cooling at 4°C for 10 min. The relative expression level of genes was
119 normalized to the β -actin level by using the $2^{-\Delta\Delta Ct}$ method.

120

121 **Statistical analysis**

122 Data were statistically analyzed using IBM SPSS Statistics program (version 23; IBM Corp.,
123 Armonk, NY, USA). One-way analysis of variance was followed by a post hoc Duncan's
124 multiple comparisons test at $P < 0.05$. Data are presented as mean \pm standard deviation.

125

126 **Results and Discussion**

127 **KI 31-W and KI 36-W significantly reduce lipid accumulation of 3T3-L1 cells**

128 To examine the cell viability of 3T3-L1 cells in the presence of KI31-W or KI 36-W, the cells
129 were treated with the indicated concentrations (0, 0.09, 0.18, 0.35, and 0.7 mg/mL) of KI 31-
130 W or KI 36-W and the cell viability was determined using MTT assay. Figure 1A and 1B
131 indicated that bioconversion of whey by *P. pentosaceus* KI 31 or *L. sakei* KI 36 did not affect
132 3T3-L1 cell viability. Decreased lipid accumulation in mature 3T3-L1 cells in the presence of
133 KI 31-W or KI 36-W was observed (Fig. 2A and 2B, respectively). A significantly reduced lipid
134 accumulation was evident in 3T3-L1 cells treated with KI 31-W at 0.35 and 0.7 mg/mL (Fig.
135 2A). Likewise, lipid accumulation in 3T3-L1 cells was significantly inhibited by KI 36-W
136 treatment at 0.18, 0.35, and 0.7 mg/mL. In particular, the lipid accumulation was reduced by
137 over 50% following treatment with 0.7 mg/mL KI 36-W. (Fig. 2B). However, non-bioconverted
138 whey did not reduce lipid accumulation in 3T3-L1 cells (Fig. 2C). Although whey protein and
139 its derivatives confer health benefits against several metabolic diseases (Patel, 2015), it has not
140 been well established that whey protein prevents adipogenesis. Enriched whey protein fractions
141 inhibit adipogenesis of 3T3-L1 (Rajic et al., 2010). More recently, D'Souza et al. (D'Souza et
142 al., 2020) demonstrated that whey protein hydrolyzed by pepsin and pancreatin enhances 3T3-
143 L1 adipocyte differentiation and triacylglycerol accumulation. However, it has not yet been
144 reported that bioconversion of whey exerts an anti-adipogenic effect. Our findings showed that

145 bioconversion of whey by LAB effectively inhibits adipogenesis without decreasing the
146 proliferation of 3T3-L1 cells. Further, our observation demonstrated that, among the proteins
147 separated by SDS-PAGE, bovine serum albumin from bioconversion of whey by LAB was
148 decreased compared to the protein of non-bioconverted whey (Fig. 2D). It has been shown that
149 bovine serum, which contains albumin, facilitates the proliferation and differentiation of cells
150 (Cho et al., 2018), assuming that the decreased bovine serum albumin by the bioconversion
151 may be associated with the reduction of adipogenic differentiation.

152

153 **KI 31-W and KI 36-W down-regulate mRNA expression of genes related to adipogenesis** 154 **and lipogenesis**

155 As shown in Fig 3A, KI 31-W remarkably decreased mRNA expression of PPAR γ at doses
156 of 0.35 and 0.7 mg/mL in 3T3-L1 cells. Similar effects on the down-regulation of aP2 and LPL
157 were seen in the cells treated with 0.35 and 0.7 mg/mL. Figure 3B demonstrated that KI 36-W
158 also significantly down-regulated PPAR γ at doses of 0.35 and 0.7 mg/mL in 3T3-L1 cells.
159 However, aP2 mRNA expression was significantly decreased at 0.7 mg/mL KI36-W, but not at
160 0.35 mg/mL. In addition, LPL mRNA expression was strongly inhibited by KI 36-W at 0.09 to
161 0.7 mg/mL. Exposure of 3T3-L1 cells to dexamethasone, isobutylmethylxanthine, insulin, and
162 fetal bovine serum, triggers a cascade of transcriptional activity, resulting in the rapid induction
163 of regulators, such as PPAR γ (Morrison and Farmer, 2000). Activation of PPAR γ positively
164 regulates downstream target genes, such as aP2 and LPL, associated with growth and
165 differentiation (Farmer, 2005). Adipogenesis is strongly regulated by sequential activation of
166 various transcription factors, such as PPAR γ (Li et al., 2016). A dramatic increase in PPAR γ
167 gene expression was observed 5 days after the induction of 3T3-L1 cell differentiation (White
168 and Stephens, 2010). The reduced expression of PPAR γ was observed from an early stage (day

169 3) and final late-stage (day 8) during 3T3-L1 cell differentiation (Li et al., 2016). Our present
170 study also showed that both KI 31-W and KI 36-W significantly suppressed PPAR γ gene
171 expression 9 days after the induction of differentiation. In addition, increased PPAR γ expression
172 sequentially up-regulates specific adipocyte genes, such as aP2 and LPL, to control fatty acid
173 metabolism (Hassan et al., 2007). As a member of the fatty acid-binding proteins, aP2, which
174 is highly expressed in mature adipocytes, plays an essential role in the intracellular fatty acid
175 transport and metabolism critical for maintaining glucose and lipid homeostasis (Elmasri et al.,
176 2009). LPL plays a pivotal role in the generation of fatty acids and their uptake by cells. Hence,
177 the reduction of LPL expression during adipocyte differentiation may lead to decreased lipid
178 storage in cells (Linehan et al., 2012).

179 In conclusion, we found that bioconversion of whey by LAB has the potential to suppress
180 the adipogenic differentiation of 3T3-L1 cells, although it does not inhibit cell proliferation.
181 Bioconversion of whey by LAB effectively and markedly reduces a key adipogenesis
182 transcription factor, PPAR γ , as well as specific lipogenesis genes, aP2 and LPL, consequently
183 attenuating the adipogenic differentiation. To our best knowledge, this study is the first to
184 demonstrate that bioconversion of whey has a beneficial effect.

185

186 **Conflict of Interest**

187 The authors declare that they have no conflict of interest.

188

189 **Acknowledgments**

190 This work was supported by the Korea Institute of Planning and Evaluation for Technology in
191 Food, Agriculture and Forestry (IPET) through the High Value-added Food Technology
192 Development Program, funded by the Ministry of Agriculture, Food and Rural Affairs

193 (MAFRA) (318091-03-2-HD050).

194

195 **Author Contributions**

196 Conceptualization: Kang SS. Data curation: Lee JS, Hyun IK, Yoon JW, Seo HJ, Kang SS.
197 Formal analysis: Lee JS, Hyun IK, Yoon JW, Seo HJ. Methodology: Yoon JW, Seo HJ, Kang
198 SS. Software: Lee JS, Hyun IK. Validation: Lee JS, Hyun IK, Yoon JW, Seo HJ. Investigation:
199 Lee JS, Hyun IK, Yoon JW, Seo HJ. Writing - original draft: Lee JS, Hyun IK. Writing - review
200 & editing: Lee JS, Hyun IK, Yoon JW, Seo HJ, Kang SS.

201

202 **Ethics Approval**

203 This article does not require IRB/IACUC approval because there are no human and animal
204 participants.

205

206 **References**

207 Asha S, Vidyavathi M. 2009. Cunninghamella--a microbial model for drug metabolism studies--
208 -A review. *Biotechnol Adv* 27:16-29.

209 Bjornshave A, Hermansen K. 2014. Effects of dairy protein and fat on the metabolic syndrome
210 and type 2 diabetes. *Rev Diabet Stud* 11:153-166.

211 Boguta AM, Bringel F, Martinussen J, Jensen PR. 2014. Screening of lactic acid bacteria for
212 their potential as microbial cell factories for bioconversion of lignocellulosic feedstocks.
213 *Microb Cell Fact* 13:97.

214 Cho H, Lee A, Kim K. 2018. The effect of serum types on chondrogenic differentiation of
215 adipose-derived stem cells. *Biomater Res* 22:6.

216 D'souza K, Mercer A, Mawhinney H, Pulinilkunnil T, Udenigwe CC, Kienesberger PC. 2020.
217 Whey peptides stimulate differentiation and lipid metabolism in adipocytes and

218 ameliorate lipotoxicity-induced insulin resistance in muscle cells. *Nutrients* 12:425.

219 Domingues L, Dantas MM, Lima N, Teixeira JA. 1999. Continuous ethanol fermentation of
220 lactose by a recombinant flocculating *saccharomyces cerevisiae* strain. *Biotechnol*
221 *Bioeng* 64:692-697.

222 Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J,
223 Cataltepe S. 2009. Fatty acid binding protein 4 is a target of vegf and a regulator of cell
224 proliferation in endothelial cells. *FASEB J* 23:3865-3873.

225 Farmer SR. 2005. Regulation of ppargamma activity during adipogenesis. *Int J Obes (Lond)* 29
226 Suppl 1:S13-16.

227 Hassan M, El Yazidi C, Landrier JF, Lairon D, Margotat A, Amiot MJ. 2007. Phloretin enhances
228 adipocyte differentiation and adiponectin expression in 3T3-L1 cells. *Biochem Biophys*
229 *Res Commun* 361:208-213.

230 Hegazy ME, Mohamed TA, Elshamy AI, Mohamed AE, Mahalel UA, Reda EH, Shaheen AM,
231 Tawfik WA, Shahat AA, Shams KA, Abdel-Azim NS, Hammouda FM. 2015. Microbial
232 biotransformation as a tool for drug development based on natural products from
233 mevalonic acid pathway: A review. *J Adv Res* 6:17-33.

234 Lee NK, Paik HD. 2017. Bioconversion using lactic acid bacteria: Ginsenosides, gaba, and
235 phenolic compounds. *J Microbiol Biotechnol* 27:869-877.

236 Li KK, Liu CL, Shiu HT, Wong HL, Siu WS, Zhang C, Han XQ, Ye CX, Leung PC, Ko CH.
237 2016. Cocoa tea (*Camellia ptilophylla*) water extract inhibits adipocyte differentiation
238 in mouse 3T3-L1 preadipocytes. *Sci Rep* 6:20172.

239 Lin T, Lin C, Wang Y. 2002. Linoleic acid isomerase activity in enzyme extracts from
240 *Lactobacillus acidophilus* and *Propionibacterium freudenreichii* ssp. *Shermanii*. *J Food*
241 *Sci* 67:1502-1505.

242 Linehan C, Gupta S, Samali A, O'connor L. 2012. Bisphenol A-mediated suppression of LPL
243 gene expression inhibits triglyceride accumulation during adipogenic differentiation of
244 human adult stem cells. *PLoS One* 7:e36109.

245 Marshall K. 2004. Therapeutic applications of whey protein. *Altern Med Rev* 9:136-156.

246 Morrison RF, Farmer SR. 2000. Hormonal signaling and transcriptional control of adipocyte
247 differentiation. *J Nutr* 130:3116S-3121S.

248 Patel S. 2015. Emerging trends in nutraceutical applications of whey protein and its derivatives.
249 *J Food Sci Technol* 52:6847-6858.

250 Rajic A, Dhulia J, Hosking CG, Autelitano DJ. 2010. A novel dairy-derived isolate that inhibits
251 adipogenesis and significantly reduces weight gain in a high fat animal model. *Int Dairy*
252 *J* 20:480-486.

253 Smitha M, Singh S, Singh R. 2017. Microbial biotransformation: A process for chemical
254 alterations. *J Bacteriol Mycol Open Access* 4:00085.

255 Sornplang P, Piyadeatsoontorn S. 2016. Probiotic isolates from unconventional sources: A
256 review. *J Anim Sci Technol* 58:26.

257 Spiegelman BM, Flier JS. 2001. Obesity and the regulation of energy balance. *Cell* 104:531-
258 543.

259 Walzem RL, Dillard CJ, German JB. 2002. Whey components: Millennia of evolution create
260 functionalities for mammalian nutrition: What we know and what we may be
261 overlooking. *Crit Rev Food Sci Nutr* 42:353-375.

262 White UA, Stephens JM. 2010. Transcriptional factors that promote formation of white adipose
263 tissue. *Mol Cell Endocrinol* 318:10-14.

264 Yang H, Lee SH, Ji H, Kim JE, Yoo R, Kim JH, Suk S, Huh CS, Park JHY, Heo YS, Shin HS,
265 Kim BG, Lee KW. 2019. Orobol, an enzyme-convertible product of genistein, exerts

266 anti-obesity effects by targeting casein kinase 1 epsilon. Sci Rep 9:8942.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286


287

288

289

ACCEPTED

290 **Figure legends**




291

292

293 **Fig. 1.** Cell viability of 3T3-L1 adipocytes in the presence of KI 31-W and KI 36-W. The cell
294 viability was determined by MTT assay after 3T3-L1 cells were treated with KI 31-W or KI 36-
295 W for 24 h. The results were obtained from three independent experiments.

296



297

298 **Fig. 2.** Effect of KI 31-W and KI 36-W on lipid accumulation in 3T3-L1 adipocytes.

299 Determination of lipid content by Oil Red O staining in fully differentiated 3T3-L1 adipocytes


300 treated with KI 31-W (A) or KI 36-W (B). Images represent microscopy of Oil Red O-stained

301 cells. The results were obtained from three independent experiments. (C) lipid accumulation in

302 3T3-L1 cells in the presence of non-bioconverted whey was determined by Oil Red O staining.

303 (D) protein profiles of non-bioconverted and bioconversion of whey were analyzed by SDS-

304 PAGE. M: size marker.



305

306 **Fig. 3.** Effect of KI 31-W and KI 36-W on the mRNA levels of adipogenesis- and lipogenesis-
 307 related genes in 3T3-L1 adipocytes. The mRNA expression of PPAR γ , aP2, and LPL in 3T3-
 308 L1 adipocytes in the presence of KI 31-W or KI 36-W were quantified by real-time RT-PCR
 309 analysis. The results were obtained from three independent experiments.

310